Tailored tamoxifen treatment for breast cancer patients: A perspective

Clinical Breast Cancer

Volumn 15, Issue 4, 2015, Pages 241-244

  Jager, Nynke G L ^a   Linn, Sabine C ^b,c   Schellens, Jan H M ^b,d   Beijnen, Jos H ^a,b,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Endoxifen; Estrogen receptor positive breast cancer; Metabolite levels; Therapeutic Drug Monitoring; Treatment individualization

Indexed keywords

AFIMOXIFENE; DRUG METABOLITE; ENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; GENOTYPE; HUMAN; INDIVIDUALIZATION; PERSONALIZED MEDICINE; PHENOTYPE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST NEOPLASMS; FEMALE; PROCEDURES;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; PRECISION MEDICINE; TAMOXIFEN;

EID: 84946493236     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.04.005     Document Type: Note

References (43)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.; Lyon, France: International Agency for Research on Cancer, 2013.
2. A. Shiau, D. Barstad, P. Loria, and et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
3. I.E. Smith, and M. Dowsett Aromatase inhibitors in breast cancer N Engl J Med 348 2003 2431 2442
4. C. Davies, H. Pan, J. Godwin, and et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
5. R. Gray, D. Rea, and K. Handley aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer (abstract 5) J Clin Oncol 2013 31 No18 supplement
6. C. Davies, J. Godwin, R. Gray, and et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
7. K. Beelen, W. Zwart, and S.C. Linn Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 9 2012 529 541
8. H. Oosterkamp, E. Hijmans, T. Brummelkamp, and et al. USP9X downregulation renders breast cancer cells resistant to tamoxifen Cancer Res 74 2014 3810 3820
9. S.F. Teunissen, H. Rosing, M.D. Seoane, and et al. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques J Pharm Biomed Anal 55 2011 518 526
10. T.E. Murdter, W. Schroth, L. Bacchus-Gerybadze, and et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma Clin Pharmacol Ther 89 2011 708 717
11. M. O'Neill, P. Heckelman, C. Koch, and K. Roman The Merck Index 14th ed. 2006 Merck Research Laboratories Whitehouse Station, NJ
12. M.D. Johnson, H. Zuo, K.H. Lee, and et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 85 2004 151 159
13. N.G.L. Jager, H. Rosing, J.H.M. Schellens, S.C. Linn, and J.H. Beijnen Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care Breast Cancer Res Treat 143 2014 477 483
14. X. Wu, J. Hawse, M. Subramaniam, M. Goetz, J. Ingle, and T. Spelsberg The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells Cancer Res 69 2009 1722 1727
15. M.F. Barginear, M. Jaremko, I. Peter, and et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the Antiestrogenic Activity Score Clin Pharmacol Ther 90 2011 605 611
16. W. Irvin Jr., C. Walko, K. Weck, and et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study J Clin Oncol 29 2011 3232 3239
17. Y. Jin, Z. Desta, V. Stearns, and et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 2005 30 39
18. M.P. Goetz, S.K. Knox, V.J. Suman, and et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 2007 113 121
19. W. Schroth, M.P. Goetz, U. Hamann, and et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treate with tamoxifen JAMA 302 2009 1429 1436
20. K. Kiyotani, T. Mushiroda, C.K. Imamura, and et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients J Clin Oncol 28 2010 1287 1293
21. S.E. Damodaran, S.C. Pradhan, G. Umamaheswaran, D. Kadambari, K.S. Reddy, and C. Adithan Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy Cancer Chemother Pharmacol 70 2012 75 81
22. J.M. Rae, S. Drury, D.F. Hayes, and et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients J Natl Cancer Inst 104 2012 452 460
23. S.A. Nowell, J. Ahn, J.M. Rae, and et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 2005 249 258
24. P. Wegman, S. Elingarami, J. Carstensen, O. Stål, B. Nordenskjöld, and S. Wingren Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 2007 R7
25. M. Regan CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 Trial J Natl Cancer Inst 104 2012 441 451
26. H. Brauch, W. Schroth, M. Goetz, and et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters J Clin Oncol 31 2013 176 180
27. M. Province, M. Goetz, H. Brauch, and et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations Clin Pharmacol Ther 95 2014 216 227
28. M. Province, R. Altman, and T. Klein Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium Clin Pharmacol Ther 96 2014 144 146
29. V. Stearns Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 2003 1758 1764
30. S. Borges, Z. Desta, L. Li, and et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 2006 61 74
31. A.J. De Graan, S.F. Teunissen, F.Y. de Vos, and et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment J Clin Oncol 29 2011 3240 3246
32. F.L. Opdam, V.O. Dezentje, J. den Hartigh, and et al. The use of the (13)C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels Cancer Chemother Pharmacol 71 2013 593 601
33. L.R. Ayres, A.D. Baldoni, A.P. Borges, and L.R. Pereira Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer Int J Clin Pharm 36 2014 45 54
34. L. Madlensky, L. Natarajan, S. Tchu, and et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes Clin Pharmacol Ther 89 2011 718 725
35. J. Hawse, M. Subramaniam, M. Cicek, and et al. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens PLoS One 8 2013 e54613
36. I.Y. Gong, W. Teft, J. Ly, and et al. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts Breast Cancer Res Treat 450 2013 61 69
37. P.Y. Maximov, R.E. McDaniel, D.J. Fernandes, and et al. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes Br J Pharmacol 171 2014 5624 5635
38. D. Bratherton, C. Brown, R. Buchanan, and et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd Br J Cancer 50 1984 199 205
39. H.W. Ward Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels Br Med J 1 1973 13 14
40. P. Sismondi, N. Biglia, E. Volpi, M. Giai, and T. de Grandis Tamoxifen and endometrial cancer Ann N Y Acad Sci 734 1994 310 321
41. H. Adam, J. Patterson, and J. Kemp Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers Cancer Treat Rep 64 1980 761 764
42. N.G.L. Jager, H. Rosing, J.H.M. Schellens, and J.H. Beijnen Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects Bioanalysis 6 2014 2999 3009
43. M.V. Antunes, S. Raymundo, V. de Oliveira, and et al. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots Talanta 132 2015 775 784